Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Talaris Therapeutics, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/15/2022 |
8-K
| Quarterly results|
Docs:
|
"Three months ended June 30, 2022 2021 Operating expenses Research and development $ 13,187 $ 7,570 General and administrative $ 5,228 $ 3,487 Total operating expenses 18,415 11,057 Loss from operations Interest and other income , net $ 319 $ Net loss attributable to common stockholders $ $ Net loss per common share, basic and diluted $ $ Weighted average number of common shares outstanding used in computation of net loss per common share, basic and diluted $ 41,088,085 $ 27,373,165 Balance Sheets Selected Financial Data June 30, December 31, 2022 2021 Cash, cash equivalents and marketable securities $ 207,112 $ 243,971 Working capital 204,706 238,527 Total assets 220,916 251,422 Other liabilities 2,822 626 Total liabilities 10,174 8,613 Total convertible preferred stock and stockholders’ ..." |
|
| 05/12/2022 |
8-K
| Quarterly results |
| 11/12/2021 |
8-K
| Quarterly results |
| 08/12/2021 |
8-K
| Quarterly results |
| 06/14/2021 |
8-K
| Quarterly results |
|
|